Shareholders of pharma companies Biovail and Valeant voted to approve their merger, and the new company is now called Valeant Pharmaceuticals International. Valeant markets Migranal dihydroergotamine nasal spray in the US, and Biovail had been partnered with Alexza on the development of Staccato loxapine since February 2010. FDA action on the Staccato loxapine NDA is expected next month. The new company is headquartered in Mississauga, Ontario, Canada. Read the company’s press release.
Biovail and Valeant merge
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
